Indaptus Therapeutics, Inc. completed a private placement of 20,338,974 shares of common stock to purchasers party to the Stock Purchase Agreement dated September 8, 2026. The company received aggregate gross proceeds of approximately $24.0 million before deducting offering expenses. This closing follows an extension of the outside date from September 29, 2026, to October 16, 2026. Indaptus Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for rare diseases.
